234 related articles for article (PubMed ID: 18800611)
1. [Molecular targeted therapy for renal cell carcinoma].
Kakehi Y
Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
[No Abstract] [Full Text] [Related]
2. Renal-cell carcinoma--molecular pathways and therapies.
Brugarolas J
N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
[No Abstract] [Full Text] [Related]
3. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Vira MA; Novakovic KR; Pinto PA; Linehan WM
BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
[No Abstract] [Full Text] [Related]
4. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
5. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
6. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
7. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
8. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
10. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
[TBL] [Abstract][Full Text] [Related]
11. [Molecular basis of targeted therapy in metastatic renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():184-6. PubMed ID: 18751979
[TBL] [Abstract][Full Text] [Related]
12. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Rini BI
Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment.
Rini BI; Shah SN
Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
[No Abstract] [Full Text] [Related]
14. Editorial comment.
Vaishampayan U
Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
[No Abstract] [Full Text] [Related]
15. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
16. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
17. [Renal cell carcinoma].
Oya M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
[No Abstract] [Full Text] [Related]
18. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
19. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
20. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]